Day One Biopharmaceuticals, Inc. (NASDAQ:DAWN) Receives $30.57 Consensus Price Target from Brokerages

Shares of Day One Biopharmaceuticals, Inc. (NASDAQ:DAWN - Get Free Report) have been assigned an average rating of "Buy" from the eight analysts that are covering the stock, Marketbeat.com reports. Seven analysts have rated the stock with a buy recommendation and one has given a strong buy recommendation to the company. The average 1 year price objective among brokerages that have issued a report on the stock in the last year is $30.57.

Several brokerages recently issued reports on DAWN. JPMorgan Chase & Co. dropped their price objective on shares of Day One Biopharmaceuticals from $39.00 to $34.00 and set an "overweight" rating for the company in a research note on Wednesday, March 5th. HC Wainwright reiterated a "buy" rating and issued a $36.00 price target on shares of Day One Biopharmaceuticals in a research note on Thursday, April 3rd. The Goldman Sachs Group lowered their price target on Day One Biopharmaceuticals from $39.00 to $27.00 and set a "buy" rating on the stock in a report on Tuesday, March 25th. Needham & Company LLC reduced their price objective on shares of Day One Biopharmaceuticals from $30.00 to $27.00 and set a "buy" rating for the company in a research note on Wednesday, May 7th. Finally, Wedbush restated an "outperform" rating and set a $25.00 target price on shares of Day One Biopharmaceuticals in a report on Wednesday, May 7th.

Insider Buying and Selling at Day One Biopharmaceuticals

In other Day One Biopharmaceuticals news, CEO Jeremy Bender sold 13,964 shares of the business's stock in a transaction dated Friday, May 16th. The stock was sold at an average price of $6.26, for a total value of $87,414.64. Following the completion of the transaction, the chief executive officer now directly owns 145,737 shares of the company's stock, valued at approximately $912,313.62. The trade was a 8.74% decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through the SEC website. Also, General Counsel Adam Dubow sold 4,552 shares of the business's stock in a transaction that occurred on Friday, May 16th. The shares were sold at an average price of $6.26, for a total value of $28,495.52. Following the completion of the sale, the general counsel now owns 47,136 shares in the company, valued at $295,071.36. The trade was a 8.81% decrease in their position. The disclosure for this sale can be found here. Insiders have sold a total of 26,725 shares of company stock valued at $167,299 in the last three months. 6.20% of the stock is currently owned by company insiders.

Institutional Investors Weigh In On Day One Biopharmaceuticals

A number of institutional investors have recently modified their holdings of the business. GF Fund Management CO. LTD. bought a new stake in shares of Day One Biopharmaceuticals during the fourth quarter worth about $27,000. Quantbot Technologies LP purchased a new position in shares of Day One Biopharmaceuticals in the 1st quarter worth about $82,000. Pallas Capital Advisors LLC bought a new position in Day One Biopharmaceuticals during the first quarter valued at $87,000. Wealth Enhancement Advisory Services LLC bought a new stake in shares of Day One Biopharmaceuticals in the first quarter valued at approximately $88,000. Finally, Magnetar Financial LLC purchased a new position in shares of Day One Biopharmaceuticals during the 1st quarter valued at $90,000. Institutional investors own 87.95% of the company's stock.

Day One Biopharmaceuticals Stock Performance

DAWN traded down $0.09 during trading on Monday, hitting $6.41. The stock had a trading volume of 1,321,774 shares, compared to its average volume of 1,130,938. The stock has a 50 day simple moving average of $6.86 and a two-hundred day simple moving average of $9.59. Day One Biopharmaceuticals has a twelve month low of $6.08 and a twelve month high of $16.76. The company has a market capitalization of $649.72 million, a PE ratio of -9.03 and a beta of -1.30.

Day One Biopharmaceuticals (NASDAQ:DAWN - Get Free Report) last issued its earnings results on Tuesday, May 6th. The company reported ($0.35) earnings per share (EPS) for the quarter, topping the consensus estimate of ($0.46) by $0.11. The firm had revenue of $30.76 million during the quarter, compared to analysts' expectations of $30.28 million. Day One Biopharmaceuticals had a negative net margin of 42.66% and a negative return on equity of 14.98%. On average, equities research analysts anticipate that Day One Biopharmaceuticals will post -0.72 EPS for the current year.

About Day One Biopharmaceuticals

Day One Biopharmaceuticals, Inc, a clinical-stage biopharmaceutical company, develops and commercializes targeted therapies for patients with genomically defined cancers. Its lead product candidate is tovorafenib, an oral brain-penetrant type II pan-rapidly accelerated fibrosarcoma kinase inhibitor that is in Phase II clinical trial for pediatric patients with relapsed/ refractory low-grade glioma.